Jayson Rieger - Mar 14, 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
CEO and President, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Mar 14, 2025
Transactions value $
$0
Form type
4
Date filed
3/18/2025, 06:45 PM
Previous filing
Nov 26, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +850K $0.00 850K Mar 14, 2025 Common Stock 850K $0.89 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/8th of the total shares subject to the option shall vest on September 14, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date.